Sep 28 – Oct 4, 2026 · 6 new studies · Orthopaedic Oncology archive · All weeks
The new Orthopaedic Oncology research The Reduction sent the week of Sep 28 – Oct 4, 2026, with the week’s most recent reviews, each with a one-line summary.
Get papers like these by email, free: subscribe to The Reduction, focused on your interests, on the days you pick.
Good Quality of Life 3 Decades After Rotationplasty: A Cross-Sectional Study.
Thirty-three rotationplasty survivors followed about 33 years reported good quality of life, higher than other lower-extremity sarcoma survivors, with only physical functioning below general-population levels.
In 746 oncologic rotationplasty patients across 26 studies, 34% had complications, mostly osseous construct, vascular, and wound issues, concentrated early (vascular within 14 days), making it a durable option with front-loaded risk.
In retroperitoneal sarcoma patients, sarcopenia (lowest-quartile psoas index) was linked to longer hospital stays after resection, though not more complications, suggesting preoperative psoas measurement could guide prehabilitation or tailored ERAS pathways.
In 645 resected soft tissue sarcomas, lymphovascular invasion (7%) independently tripled the risk of distant metastasis but not local recurrence or survival; authors now image the chest more often in these patients.
Long-term follow-up shows bipolar hemiarthroplasty for proximal femur bone tumor reconstruction offers low mechanical failure and acetabular wear rates over 15 years.
Vitamin D decreases tumor cell growth and invasiveness in primary malignant bone tumors in vitro.
In vitro study found active vitamin D (1,25D3) reduced viability, migration, and induced cell-cycle arrest in osteosarcoma cells, suggesting a possible therapeutic role in select primary bone tumors.
Home · All weeks · Archive · Subscribe · FAQ
© 2026 The Reduction